Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
暂无分享,去创建一个
Jessica Katz | Hermann Einsele | Paul Richardson | Philippe Moreau | Meral Beksac | Morio Matsumoto | M. Dimopoulos | H. Einsele | A. Palumbo | S. Lonial | P. Richardson | M. Taniwaki | A. Belch | D. Reece | R. Orlowski | P. Moreau | M. Matsumoto | S. Jesus | J. San-Miguel | A. Singhal | M. Mateos | D. White | Eric Bleickardt | Kenneth C Anderson | Masafumi Taniwaki | Christoph Röllig | Andrew Belch | Sagar Lonial | I. Špička | Donna Reece | Jesus San-Miguel | Robert Z Orlowski | Antonio Palumbo | Andrew Spencer | Ivan Spicka | A. Spencer | K. Wu | H. Magen | C. Röllig | Meletios Dimopoulos | Maria-Victoria Mateos | Darrell White | Sebastian Grosicki | Adam Walter-Croneck | Hila Magen | Heather Oakervee | Ka Lung Wu | Anil Singhal | Valerie Poulart | S. Grosicki | H. Oakervee | A. Walter-Croneck | E. Bleickardt | V. Poulart | J. Katz | K. Anderson | M. Beksaç | A. Walter‐Croneck | I. Spicka
[1] S·哈特尔. Clinical assessment of m-protein response in multiple myeloma , 2017 .
[2] Aspire Investigators,et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .
[3] Michael L. Wang,et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.
[4] S. Jagannath,et al. Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma , 2014 .
[5] Michael D. Robbins,et al. Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells , 2014, Molecular and Cellular Biology.
[6] C. McCudden,et al. Abstract 2563: Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma , 2014 .
[7] Michael L. Wang,et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. , 2014, Blood.
[8] S. Latour,et al. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization , 2014, The Journal of experimental medicine.
[9] Don M. Benson,et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC , 2013, Cancer Immunology, Immunotherapy.
[10] C. Berking,et al. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.
[11] J. Genzen,et al. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis , 2011, British journal of haematology.
[12] S. Tangye,et al. SLAM family receptors and SAP adaptors in immunity. , 2011, Annual review of immunology.
[13] P. Voorhees,et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. , 2010, Clinical chemistry.
[14] M. Dimopoulos,et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.
[15] N. Munshi,et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.
[16] F. Zhan,et al. CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.
[17] F. Zhan,et al. CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008 .
[18] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.